AVEO Pharmaceuticals Company Profile (NASDAQ:AVEO)

About AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals logoAVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AVEO
  • CUSIP: 05358810
  • Web: www.aveopharma.com
Capitalization:
  • Market Cap: $278.11 million
  • Outstanding Shares: 110,362,000
Average Prices:
  • 50 Day Moving Avg: $1.65
  • 200 Day Moving Avg: $0.93
  • 52 Week Range: $0.50 - $3.19
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 22.55
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.84 million
  • Price / Sales: 71.28
  • Book Value: $0.04 per share
  • Price / Book: 62.00
Profitability:
  • EBIDTA: ($29,880,000.00)
  • Net Margins: -728.85%
  • Return on Equity: -836.92%
  • Return on Assets: -87.50%
Debt:
  • Debt-to-Equity Ratio: 2.16%
  • Current Ratio: 2.52%
  • Quick Ratio: 2.52%
Misc:
  • Average Volume: 5.31 million shs.
  • Beta: 1.37
  • Short Ratio: 0.42
 
Frequently Asked Questions for AVEO Pharmaceuticals (NASDAQ:AVEO)

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) released its earnings results on Thursday, May, 4th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.00. The business earned $2.53 million during the quarter. AVEO Pharmaceuticals had a negative return on equity of 836.92% and a negative net margin of 728.85%. View AVEO Pharmaceuticals' Earnings History.

Where is AVEO Pharmaceuticals' stock going? Where will AVEO Pharmaceuticals' stock price be in 2017?

2 brokerages have issued 12-month target prices for AVEO Pharmaceuticals' shares. Their forecasts range from $2.00 to $3.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $2.50 in the next year. View Analyst Ratings for AVEO Pharmaceuticals.

Are investors shorting AVEO Pharmaceuticals?

AVEO Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totalling 3,657,353 shares, an increase of 63.9% from the June 15th total of 2,231,389 shares. Based on an average daily trading volume, of 16,762,289 shares, the short-interest ratio is presently 0.2 days. Currently, 4.2% of the company's stock are short sold.

Who are some of AVEO Pharmaceuticals' key competitors?

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the folowing people:

  • Michael P. Bailey, President, Chief Executive Officer, Director
  • Matthew Dallas, Chief Financial Officer
  • Michael N. Needle M.D., Chief Medical Officer
  • Henri A. Termeer, Lead Out Side Director
  • Kenneth M. Bate, Independent Director
  • Anthony B. Evnin Ph.D., Independent Director
  • Robert C. Young M.D., Independent Director

How do I buy AVEO Pharmaceuticals stock?

Shares of AVEO Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO Pharmaceuticals stock can currently be purchased for approximately $2.48.


MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)
Community Ranking:  2.3 out of 5 ( )
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  233
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AVEO Pharmaceuticals (NASDAQ:AVEO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.50 (0.81% upside)

Analysts' Ratings History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/13/2017FBR & CoReiterated RatingOutperform$3.00HighView Rating Details
6/24/2017Piper Jaffray CompaniesSet Price TargetBuy$2.00HighView Rating Details
(Data available from 7/22/2015 forward)

Earnings

Earnings History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Earnings by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)
Earnings History by Quarter for AVEO Pharmaceuticals (NASDAQ AVEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.12)($0.12)$2.53 millionViewN/AView Earnings Details
11/4/2016Q3 2016($0.12)($0.07)$0.99 millionViewN/AView Earnings Details
5/10/2016Q1($0.12)($0.13)$1.00 million$1.20 millionViewN/AView Earnings Details
3/15/2016Q415($0.04)($0.11)$3.60 millionViewN/AView Earnings Details
11/9/2015Q315($0.09)$0.14$15.16 millionViewN/AView Earnings Details
8/10/2015Q2($0.16)($0.10)$0.13 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.21)$0.13 millionViewN/AView Earnings Details
3/6/2015Q314($0.28)($0.27)$0.12 millionViewListenView Earnings Details
11/5/2014Q3 2014($0.27)($0.28)$0.33 million$0.87 millionViewN/AView Earnings Details
8/11/2014Q214($0.38)($0.35)$0.35 million$1.85 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.33)($0.12)$0.38 million$15.29 millionViewN/AView Earnings Details
3/13/2014Q413($0.33)($0.32)$0.14 million$0.32 millionViewListenView Earnings Details
11/4/2013Q313($0.47)($0.47)$0.23 million$0.32 millionViewN/AView Earnings Details
8/1/2013Q213($0.56)($0.62)$4.30 million$0.32 millionViewN/AView Earnings Details
4/29/2013Q1 2013($0.72)($0.69)$2.52 million$0.32 millionViewListenView Earnings Details
2/13/2013Q4 2012($0.77)($0.49)$14.49 million$15.53 millionViewN/AView Earnings Details
10/30/2012Q312($0.87)($0.69)$6.57 million$1.02 millionViewN/AView Earnings Details
8/2/2012($0.82)($0.68)ViewN/AView Earnings Details
5/3/2012($0.78)($0.77)ViewN/AView Earnings Details
2/14/2012($0.64)($0.58)ViewN/AView Earnings Details
11/2/2011($0.46)($0.55)ViewN/AView Earnings Details
7/28/2011($0.80)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)
2017 EPS Consensus Estimate: ($0.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.13)($0.13)($0.13)
Q2 20171($0.10)($0.10)($0.10)
Q3 20171($0.17)($0.17)($0.17)
Q4 20171($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AVEO Pharmaceuticals (NASDAQ:AVEO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 50.96%
Insider Trades by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)
Institutional Ownership by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)
Insider Trades by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/28/2017Equity Opportunities Iv GrowthMajor ShareholderBuy6,000,000$0.50$3,000,000.00View SEC Filing  
1/16/2015Matthew D DallasVPSell3,075$0.82$2,521.50View SEC Filing  
1/7/2015Michael P BaileyCEOSell4,484$0.80$3,587.20View SEC Filing  
1/30/2014Joseph VittiglioSVPSell5,430$1.64$8,905.20View SEC Filing  
3/14/2013David Brannon JohnstonCFOSell1,061$7.34$7,787.74View SEC Filing  
3/7/2013Henri A TermeerDirectorBuy55,499$6.73$373,508.27View SEC Filing  
12/13/2012Ngoc Tuan HaCEOBuy75,000$6.65$498,750.00View SEC Filing  
12/13/2012Robert C YoungDirectorBuy2,371$6.78$16,075.38View SEC Filing  
12/3/2012Robert C YoungDirectorBuy1,250$6.41$8,012.50View SEC Filing  
9/13/2012David Brannon JohnstonCFOSell1,386$10.60$14,691.60View SEC Filing  
8/8/2012Robert C YoungDirectorBuy1,000$8.63$8,630.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for AVEO Pharmaceuticals (NASDAQ:AVEO)
Latest Headlines for AVEO Pharmaceuticals (NASDAQ:AVEO)
Source:
DateHeadline
finance.yahoo.com logoHere's Why AVEO Oncology Rose as Much as 15% Today
finance.yahoo.com - July 19 at 5:26 PM
americanbankingnews.com logo AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - July 17 at 10:56 AM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Short Interest Up 63.9% in June
www.americanbankingnews.com - July 16 at 7:06 AM
bizjournals.com logoStock Performance Review on Biotech Industry -- Athersys, AVEO Pharma, Heat Biologics, and Ignyta
www.bizjournals.com - July 14 at 3:10 AM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Given "Outperform" Rating at FBR & Co
www.americanbankingnews.com - July 13 at 9:02 PM
finance.yahoo.com logoHere's Why AVEO Oncology Fell as Much as 12.7% Today
finance.yahoo.com - July 11 at 5:15 PM
nasdaq.com logoAVEO Pharmaceuticals (AVEO) Worth a Look: Stock Up 14.8% - Nasdaq
www.nasdaq.com - July 11 at 2:17 AM
finance.yahoo.com logoAVEO Pharmaceuticals Regulatory Decision from European Commission Expected Soon
finance.yahoo.com - July 10 at 9:15 PM
investorplace.com logoWhy AVEO Pharmaceuticals, Inc. (AVEO) Stock Is Soaring Today
investorplace.com - July 7 at 1:51 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Rating Reiterated by FBR & Co
www.americanbankingnews.com - June 30 at 5:20 PM
finance.yahoo.com logo2 Biotech Stocks on Analysts’ Radar: Cara Therapeutics Inc (CARA) and AVEO Pharmaceuticals, Inc. (AVEO)
finance.yahoo.com - June 30 at 4:19 PM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: AVEO Pharmaceuticals and Cara Therapeutics
finance.yahoo.com - June 28 at 4:21 PM
reuters.com logoBRIEF-Aveo Oncology gets $14 mln from Hercules Credit Facility and at-the-market stock offerings
www.reuters.com - June 28 at 1:56 AM
zacks.com logoAVEO's Kidney Cancer Candidate Gets CHMP Recommendation
www.zacks.com - June 28 at 1:56 AM
finance.yahoo.com logoHere's Why AVEO Oncology Rose As Much As 13.8% Today
finance.yahoo.com - June 27 at 8:55 PM
reuters.com logoBRIEF-Aveo Oncology gets $14 mln from Hercules Credit Facility and at-the-market stock offerings - Reuters
www.reuters.com - June 27 at 3:53 PM
seekingalpha.com logoAveo Comeback Highlights A Transatlantic Split - Seeking Alpha - Seeking Alpha
seekingalpha.com - June 27 at 3:53 PM
finance.yahoo.com logoAVEO Oncology Announces $14M in Aggregate Gross Proceeds from Hercules Credit Facility and At-the-market Stock Offerings
finance.yahoo.com - June 27 at 3:53 PM
finance.yahoo.com logoAVEO's Kidney Cancer Candidate Gets CHMP Recommendation
finance.yahoo.com - June 27 at 3:53 PM
americanbankingnews.com logoPiper Jaffray Companies Analysts Give AVEO Pharmaceuticals, Inc. (AVEO) a $2.00 Price Target
www.americanbankingnews.com - June 26 at 12:26 AM
News IconUPDATE 1-EU regulators greenlight U.S. biotech Aveo's kidney cancer drug
www.businessinsider.com - June 25 at 4:00 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - June 24 at 10:22 PM
marketwatch.com logoAVEO Pharma surges 48% on recommendation for European approval of its cancer drug - MarketWatch
www.marketwatch.com - June 23 at 4:20 PM
finance.yahoo.com logoAVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell Carcinoma
finance.yahoo.com - June 23 at 4:20 PM
finance.yahoo.com logoEU regulators greenlight U.S. biotech Aveo's kidney cancer drug
finance.yahoo.com - June 23 at 4:20 PM
finance.yahoo.com logoAVEO Pharma surges 48% on recommendation for European approval of its cancer drug
finance.yahoo.com - June 23 at 4:20 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - June 23 at 11:35 AM
finance.yahoo.com logoAVEO Reaches Enrollment Target in Pivotal Tivozanib Study
finance.yahoo.com - June 21 at 4:39 PM
finance.yahoo.com logoAVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma Reaches Enrollment Target
finance.yahoo.com - June 20 at 4:24 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - June 12 at 11:36 PM
nasdaq.com logoWhy Is AVEO Pharmaceuticals (AVEO) Up 25% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - June 9 at 9:19 PM
finance.yahoo.com logoWhy Is AVEO Pharmaceuticals (AVEO) Up 25% Since the Last Earnings Report?
finance.yahoo.com - June 9 at 4:18 PM
reuters.com logoBRIEF-Aveo Oncology announces phase 1/2 tinivo trial
www.reuters.com - June 8 at 4:28 PM
finance.yahoo.com logoAVEO Oncology Announces Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in RCC Advances to Phase 2
finance.yahoo.com - June 8 at 4:28 PM
finance.yahoo.com logoAVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting
finance.yahoo.com - June 5 at 6:06 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Short Interest Update
www.americanbankingnews.com - May 30 at 2:44 PM
americanbankingnews.com logoQ2 2017 Earnings Forecast for AVEO Pharmaceuticals, Inc. Issued By FBR & Co (AVEO)
www.americanbankingnews.com - May 24 at 8:08 AM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 23 at 1:16 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Stock Rating Reaffirmed by FBR & Co
www.americanbankingnews.com - May 22 at 11:30 AM
finance.yahoo.com logoAVEO Oncology Announces Completion of a CHMP Oral Explanation for Tivozanib as a Treatment of First-Line Renal Cell Carcinoma
finance.yahoo.com - May 19 at 9:21 AM
wsj.com logoCFO Moves: AVEO Pharmaceuticals, Community Health Systems
blogs.wsj.com - May 18 at 12:01 PM
reuters.com logoBRIEF-Aveo appoints Matthew Dallas chief financial officer
www.reuters.com - May 16 at 12:28 PM
finance.yahoo.com logoAVEO Announces Appointment of Matthew Dallas as Chief Financial Officer
finance.yahoo.com - May 16 at 12:28 PM
finance.yahoo.com logoAVEO Issues Statement Regarding the Passing of Lead Director Henri A. Termeer
finance.yahoo.com - May 15 at 4:13 PM
finance.yahoo.com logoAVEO Oncology Announces Receipt of USPTO Notice of Allowance Related to AV-353
finance.yahoo.com - May 8 at 10:43 AM
finance.yahoo.com logoAVEO Pharmaceuticals (AVEO) Q1 Loss Narrower Than Expected
finance.yahoo.com - May 5 at 8:48 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Announces Earnings Results
www.americanbankingnews.com - May 5 at 3:58 PM
finance.yahoo.com logoAVEO Reports First Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - May 4 at 8:49 PM
marketbeat.com logoAVEO reports 1Q loss
marketbeat.com - May 4 at 9:12 AM
americanbankingnews.com logoAVEO Pharmaceuticals (AVEO) Getting Somewhat Favorable News Coverage, Study Shows
www.americanbankingnews.com - May 4 at 1:01 AM

Social

Chart

AVEO Pharmaceuticals (AVEO) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by MarketBeat.com Staff